Product Launch

RNS Number:1784O
Ardana PLC
19 December 2006



                     ARDANA ANNOUNCES LAUNCH OF INVICORPTM

                      IN DENMARK FOR ERECTILE DYSFUNCTION





Edinburgh, UK, 19 December 2006;  Ardana plc (LSE:ARA), announces today that
InvicorpTM its injectable treatment for erectile dysfunction is now available
for sale in Denmark.



InvicorpTM is a combination of phentolamine mesylate and vasoactive intestinal
polypeptide and is delivered by self-administered penile injection for the
treatment of moderate to severe erectile dysfunction.  Erectile dysfunction is
male impotence resulting from an inability to have or maintain an erection
sufficient for penetration during coitus.  It is estimated that 52 per cent of
men over the age of 40 suffer at some time from erectile dysfunction and many of
them are unsuitable for treatment with existing oral therapies1.



Dr. Maureen Lindsay, Chief Executive of Ardana, said:



"We are delighted to announce the launch of InvicorpTM in Denmark today our
third marketed product in Europe and an important step in our programme for
developing our portfolio.  InvicorpTM represents a new injectable treatment
option for patients who currently have limited non- oral therapies for this
condition. "



The non oral erectile dysfunction market in the key European countries is
estimated to be Euro31.3 million and is growing at 7% per annum2.





1  Feldman H.M., et al.  Journal of Urology 1994 Jan. 151(1): 54-61.



2  IMS Health MAT February 2006.



For more information contact:

Ardana                                     Financial Dynamics
Maureen Lindsay                            (corporate/financial media relations)
Tel: + 44 (0) 131 226 8550                 Julia Phillips/John Gilbert
                                           Tel: [phone]



About Ardana



Ardana plc is a pharmaceutical company focused on the discovery, development and
marketing of innovative products to improve human reproductive health, a $25.5
billion market.



Since its foundation, Ardana has maintained a broad and balanced portfolio to
manage risk and actively pursues product and technology in-licensing and
outlicensing to maintain a robust pipeline.



Ardana's lead products are summarised below:



  * Emselex(R), a once a day treatment for overactive bladder which Ardana has
    exclusive UK marketing and promotion rights and is being distributed in
    collaboration with Novartis UK Limited;
  * StriantTM SR, a testosterone replacement therapy that has been launched by
    Ardana through its own sales force in the UK and through marketing partners
    in certain European countries, as a treatment for men with hypogonadism;
  * Teverelix LA, in development for three initial indications (prostate
    cancer, BPH and endometriosis);
  * Testosterone Cream, a trans dermal testosterone delivery system in
    development for the treatment of male hypogonadism, in Phase II trials;
  * Invicorp, an injectable combination drug treatment for erectile
    dysfunction, for which Ardana has marketing and manufacturing rights in
    Europe.
  * EP01572 a growth hormone secretagogue in late stage development for the
    diagnosis of hormone deficiency



In addition, Ardana has a strong portfolio of follow-on products in development.

Ardana is listed on the Main Market of the London Stock Exchange.



For further information please see www.ardana.co.uk


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

PRLILFITFDLTLIR